These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17594093)

  • 1. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
    Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors.
    Zhang P; Sun M; Qiu R; Tang L; Dou G; Xu B
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):971-8. PubMed ID: 21305287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.
    Peethambaram PP; Hartmann LC; Jonker DJ; de Jonge M; Plummer ER; Martin L; Konner J; Marshall J; Goss GD; Teslenko V; Clemens PL; Cohen LJ; Ahlers CM; Alland L
    Invest New Drugs; 2015 Apr; 33(2):321-31. PubMed ID: 25380635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
    Mani S; McDaid H; Hamilton A; Hochster H; Cohen MB; Khabelle D; Griffin T; Lebwohl DE; Liebes L; Muggia F; Horwitz SB
    Clin Cancer Res; 2004 Feb; 10(4):1289-98. PubMed ID: 14977827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
    Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
    Abraham J; Agrawal M; Bakke S; Rutt A; Edgerly M; Balis FM; Widemann B; Davis L; Damle B; Sonnichsen D; Lebwohl D; Bates S; Kotz H; Fojo T
    J Clin Oncol; 2003 May; 21(9):1866-73. PubMed ID: 12721265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.
    Gadgeel SM; Wozniak A; Boinpally RR; Wiegand R; Heilbrun LK; Jain V; Parchment R; Colevas D; Cohen MB; LoRusso PM
    Clin Cancer Res; 2005 Sep; 11(17):6233-9. PubMed ID: 16144926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
    Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
    J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
    Zhuang SH; Agrawal M; Edgerly M; Bakke S; Kotz H; Thambi P; Rutt A; Balis FM; Bates S; Fojo T
    Cancer; 2005 May; 103(9):1932-8. PubMed ID: 15800893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
    Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
    Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours.
    Yamamoto N; Boku N; Minami H
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):129-36. PubMed ID: 19437020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
    Jacobs S; Fox E; Krailo M; Hartley G; Navid F; Wexler L; Blaney SM; Goodwin A; Goodspeed W; Balis FM; Adamson PC; Widemann BC
    Clin Cancer Res; 2010 Jan; 16(2):750-4. PubMed ID: 20068084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.
    Widemann BC; Goodspeed W; Goodwin A; Fojo T; Balis FM; Fox E
    J Clin Oncol; 2009 Feb; 27(4):550-6. PubMed ID: 19075272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.